PhenoSense HIV is a phenotypic HIV drug resistance assay and is the most widely used phenotypic test today. PhenoSense HIV utilizes proprietary leading-edge technology for a direct, rapid and precise measure of a patient's virus' sensitivity to antiretroviral drugs. Test results allow healthcare professionals to review the level of susceptibility or resistance that an individual’s virus has has to each antiretroviral drug in order to design an individualized treatment plan. PhenoSense HIV drug resistance results are also provided with one component of viral fitness, Replication Capacity (RC).

The report form includes drug resistance information for all of the approved nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), and protease inhibitors (PIs).

Features and benefits of the PhenoSense HIV assay:

• Provides direct measurement of drug susceptibility
• Measures quantitative susceptibility data -- can measure partial susceptibility and hypersusceptibility
• Uses susceptibility cutoffs to determine when the likelihood of response begins to decrease
  Includes logical, easy-to-read report form
• Gives accurate results using plasma samples with viral loads as low as 500 HIV RNA copies/mL
• Supplements resistance results with replication capacity information to evaluate viral fitness

Click here

Click here to download slide presentation featuring vector and transfections schematics.

Reference: A Novel Phenotypic Drug Susceptibility Assay for Human Immunodeficiency Virus Type 1. C Petropoulos et al; Antimicrobial Agents and Chemotherapy, Apr. 2000, Vol. 44, No. 4, pp. 920–928

For more information on Monogram assays, services and pricing, please contact us.